<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Metyrapone: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Metyrapone: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Metyrapone: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="10156" href="/d/html/10156.html" rel="external">see "Metyrapone: Drug information"</a> and <a class="drug drug_patient" data-topicid="119109" href="/d/html/119109.html" rel="external">see "Metyrapone: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F12806507"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Metopirone</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1060385"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Diagnostic Agent, Hypothalamic-Pituitary ACTH Function</span></li></ul></div>
<div class="block dop drugH1Div" id="F196007"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="07f744cf-a2a6-46ce-9e2c-ac6954217adf">ACTH function, diagnostic test</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>ACTH function, diagnostic test:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Single-dose/overnight test: <b>Note:</b> Due to potential precipitation of acute adrenal insufficiency (crisis) in some patients, experts suggest that metyrapone should be used with extreme caution in an outpatient setting; consider administration in an inpatient environment (Kliegman 2016; Uçar 2016).</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents: Oral: 30 mg/kg as a single dose given at midnight the night before the test; maximum dose: 3,000 mg/dose</p>
<p style="text-indent:-2em;margin-left:4em;">Multiple-dose test: Children and Adolescents: Oral: 15 mg/kg/dose every 4 hours for 6 doses; <b>minimum</b> dose: 250 mg/dose; maximum dose: 750 mg/dose</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51130102"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51130103"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F195998"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="10156" href="/d/html/10156.html" rel="external">see "Metyrapone: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="332f29ee-8673-482d-a409-d995a6bac11a">Diagnostic aid, adrenal insufficiency</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diagnostic aid, adrenal insufficiency: Oral:</b> 30 mg/kg (maximum: 3 g) at midnight.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fd1ec529-f0cc-4b8f-b590-e6aa834a8769">Cushing syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cushing syndrome (off-label use):</b>
<b>Note:</b> Dosages based on retrospective/observational data and clinical experience. Metyrapone may be administered as monotherapy or occasionally in combination with other agents (eg, ketoconazole and/or mitotane); refer to protocols for details.</p>
<p style="text-indent:-2em;margin-left:4em;">Initial: <b>Oral:</b> 500 mg/day to 1 g/day in 2 to 4 divided doses; higher initial doses (eg, 1.5 g/day) may be considered in patients with ectopic ACTH syndrome or adrenocortical carcinoma (Biller 2008; Ceccato 2018; Daniel 2015a; Daniel 2015b; ES [Nieman 2015]).</p>
<p style="text-indent:-2em;margin-left:4em;">Dosage adjustment: <b>Oral:</b> Adjust daily dose in increments of 250 to 500 mg based on cortisol response (Ceccato 2018; Daniel 2015b). Usual dosage range: 500 mg/day to 4.5 g/day (Ceccato 2018; Daniel 2015a; Kamenicky 2011); maximum: 6 g/day (ES [Nieman 2015]).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991738"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doha drugH1Div" id="F50989044"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. Diagnostic response to metyrapone may be impaired in patients with cirrhosis.</p></div>
<div class="block adr drugH1Div" id="F195982"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified. Reported adverse reactions may be derived for off-label long-term use for Cushing syndrome.</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema (including peripheral edema) (Ceccato 2018; Nieman 2015; Verhelst 1991), hypertension (Nieman 2015; Verhelst 1991), hypotension</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Allergic skin rash (including allergic dermatitis) (Ceccato 2018), alopecia (Ceccato 2018; Harries-Jones 1990), exacerbation of acne (Jeffcoate 1977; Nieman 2015)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine: Adrenocortical insufficiency (Daniel 2015), hirsutism (Nieman 2015; Verhelst 1991), hypokalemia (Nieman 2015; Verhelst 1991)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distress, abdominal pain (including upper abdominal pain) (Ceccato 2018; Mancini 2010), decreased appetite (Ceccato 2018), gastric distress (Daniel 2015), nausea (Ceccato 2018), vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia, leukopenia, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia (Ceccato 2018), dizziness (Ceccato 2018), headache, sedated state</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Myalgia (Ceccato 2018; Daniel 2015)</p></div>
<div class="block coi drugH1Div" id="F195991"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to metyrapone or any component of the formulation; patients with adrenal cortical insufficiency.</p></div>
<div class="block war drugH1Div" id="F195980"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Diagnostic response to metyrapone may be impaired in patients with cirrhosis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Reduced adrenal secretory capacity: Acute adrenal insufficiency may be induced in patients with reduced adrenal secretory capacity.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thyroid disease: Response to test may be subnormal in patients with hypo- or hyperthyroidism.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings and precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Discontinue use of drugs affecting pituitary or adrenocortical function prior to administration; consider ≥5 half-lives to avoid interference. Prior to testing, assess the ability of the patient's adrenal glands to respond to exogenous ACTH.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878548"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Administration of metyrapone may induce acute adrenal insufficiency in patients with reduced adrenal secretory capacity; should be used with extreme caution in an outpatient setting; consider administration in an inpatient environment. Patients should be observed closely during administration and the following day; should only be administered under the supervision of a qualified physician experienced in the use of metyrapone (Kliegman 2016; Uçar 2016).</p></div>
<div class="block foc drugH1Div" id="F195988"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Metopirone: 250 mg</p></div>
<div class="block geq drugH1Div" id="F195977"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16323397"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Metopirone Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $55.56</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block accres drugH1Div" id="F11345045"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">Metopirone is available from HRA Pharma via special allocation only. Contact the manufacturer for additional information at 1-800-320-2112 (for outpatient prescriptions), 1-844-597-6373 (for hospital and institutional orders), or https://metopirone.com/.</p></div>
<div class="block admp drugH1Div" id="F52613321"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral:</p>
<p style="text-indent:-2em;margin-left:2em;">Single-dose/overnight test:<b> Note:</b> Due to potential precipitation of acute adrenal insufficiency (crisis) in some patients, experts suggest that metyrapone should be used with extreme caution in an outpatient setting; consider administration in an inpatient environment (Kliegman 2016; Uçar 2016). Administer dose at midnight with yogurt or milk. Blood samples should be collected the following morning (7:30 to 8:00 am). Administer prophylactic dose of cortisone acetate after samples are obtained.</p>
<p style="text-indent:-2em;margin-left:2em;">Multiple-dose test: Administer with milk or snack 3 days following ACTH test. Urine is collected for 24 hours following administration of last dose.</p></div>
<div class="block adm drugH1Div" id="F11345073"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Diagnostic aid, adrenal insufficiency:</b> Administer dose at midnight with milk/yogurt or snack. Blood samples are taken early the following morning (7:30 am to 8:00 am). May administer a prophylactic dose of glucocorticoid after samples are obtained to reduce the risk of acute adrenal insufficiency.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Cushing syndrome:</b> Administer with food or milk to minimize GI disturbance (ES [Nieman 2015]).</p></div>
<div class="block sts drugH1Div" id="F195995"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F); protect from heat. Protect from moisture.</p></div>
<div class="block usep drugH1Div" id="F53567831"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Diagnostic agent for testing hypothalamic-pituitary ACTH function (FDA approved in pediatric patients [age not specified] and adults)</p></div>
<div class="block mst drugH1Div" id="F196020"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">MetyraPONE may be confused with metyroSINE</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F196012"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F195983"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetaminophen: MetyraPONE may increase the serum concentration of Acetaminophen. More importantly, by inhibiting the conjugative metabolism of acetaminophen, metyrapone may shift the metabolism towards the oxidative route that produces a hepatotoxic metabolite. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antiseizure Agents: May diminish the diagnostic effect of MetyraPONE. Management: Consider alternatives to the use of the metyrapone test in patients taking antiseizure agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithyroid Agents: May diminish the diagnostic effect of MetyraPONE. Management: Consider alternatives to the use of the metyrapone test in patients taking antithyroid agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May diminish the diagnostic effect of MetyraPONE. Management: Consider alternatives to the use of the metyrapone test in patients taking systemic corticosteroids.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cyproheptadine: May diminish the diagnostic effect of MetyraPONE. Management: Consider alternatives to the use of the metyrapone test in patients taking cyproheptadine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Estrogen Derivatives: May diminish the diagnostic effect of MetyraPONE. Management: Consider alternatives to the use of the metyrapone test in patients taking estrogen derivatives.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Progestins: May diminish the diagnostic effect of MetyraPONE. Management: Consider alternatives to the use of the metyrapone test in patients taking progestins.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propacetamol: MetyraPONE may increase serum concentrations of the active metabolite(s) of Propacetamol. Specifically, metyrapone may increase acetaminophen exposure. More importantly, by inhibiting the conjugative metabolism of acetaminophen, metyrapone may shift the metabolism toward the oxidative route that produces a hepatotoxic metabolite. <i> Risk X: Avoid combination</i></p></div>
<div class="block dic drugH1Div" id="F11345070"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Take with milk/yogurt or snack.</p></div>
<div class="block pri drugH1Div" id="F195992"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Metyrapone crosses the placenta (Azzola 2020).</p>
<p style="text-indent:-2em;margin-left:2em;">When used as a diagnostic test during the second and third trimesters of pregnancy, the fetal pituitary responded to the enzymatic block. A subnormal response to testing may occur in pregnant patients.</p>
<p style="text-indent:-2em;margin-left:2em;">Untreated Cushing syndrome during pregnancy may cause adverse events in the mother and fetus (Bronstein 2015; Brue 2018; Kamoun 2014). Information related to metyrapone for the treatment of Cushing disease (off-label use) during pregnancy is limited. Medication may be considered for patients when surgery is not an option or for symptomatic control at initial diagnosis (ES [Nieman 2015]; ESE [Luger 2021]. When medical therapy is needed, treatment is generally started in the second or third trimesters (Bronstein 2015).</p></div>
<div class="block mopp drugH1Div" id="F53567830"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Single-dose test: ACTH, cortisol and 11-deoxycortisol concentrations measured at 8 am (Uçar 2016); 11-deoxycortisol concentrations diagnostic for adrenal insufficiency:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: &lt;210 nmol/L (Uçar 2016)</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: &lt;200 nmol/L (Wallace 2009)</p>
<p style="text-indent:-2em;margin-left:2em;">Multiple-dose test: Normal response following the test is a two- to fourfold urinary increase in 17-OHCS excretion or doubling of 17-KGS excretion.</p></div>
<div class="block rerp drugH1Div" id="F53567686"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">Normal 24-hour urinary excretion of 17-OHCS: 3 to 12 mg (increases following ACTH infusion)</p>
<p style="text-indent:-2em;margin-left:2em;">Normal response to metyrapone:</p>
<p style="text-indent:-2em;margin-left:4em;">Plasma ACTH: 44 pmol/L (200 ng/L)</p>
<p style="text-indent:-2em;margin-left:4em;">Plasma 11-desoxycortisol: Pediatric: 0.21 micromoles/L (Uçar 2016); Adult: 0.2 micromoles/L (70 mcg/L)</p>
<p style="text-indent:-2em;margin-left:4em;">24 hour urinary excretion of 17-OHCS: 2 to 4 time increase</p>
<p style="text-indent:-2em;margin-left:4em;">24 hour urinary excretion of 17-KGS: 2 time increase</p>
<p style="text-indent:-2em;margin-left:2em;">A subnormal response may be indicative of panhypopituitarism or partial hypopituitarism. An excessive response is suggestive of Cushing syndrome associated with adrenal hyperplasia.</p></div>
<div class="block pha drugH1Div" id="F11345064"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Metyrapone inhibits 11 beta-hydroxylase, preventing the conversion of 11-deoxycortisol to cortisol; blockade can be measured by the urinary increase of the metabolites of cortisol precursors in the urine (17-hydroxycorticosteroids [17-OHCS] and 17-ketogenic steroids [17-KGS]).</p></div>
<div class="block phk drugH1Div" id="F11345066"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Reduced to metyrapol (active metabolite); parent drug and metabolite also undergo glucuronide conjugation.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Metyrapone: 1.9 ± 0.7 hours; Metyrapol (active metabolite): ~4 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: ~1 hour.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine; ~5% as metyrapone (primarily as glucuronide conjugate) and ~38% as metyrapol (primarily as glucuronide conjugate).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038679"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Metycor</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Metopirone</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Metopirone</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Metopiron</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Metopirone</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Metopiron | Metopirone</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Metopirone</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Metopirone</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Metopirone</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Metopirone</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Metopirone</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Metopiron</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Metopiron</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Metopiron</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Metopiron | Metopirone | Metycor</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Metopirone</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Metopiron</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Metopiron | Metopirone</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Metopiron</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Metopiron</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Metopirone</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Metopirone</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52. doi:10.1002/cpt.377<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metyrapone-pediatric-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33305159">
<a name="33305159"></a>Azzola A, Eastabrook G, Matsui D, et al. Adrenal Cushing syndrome diagnosed during pregnancy: Successful medical management with metyrapone. <i>J Endocr Soc</i>. 2020;5(1):bvaa167. doi:10.1210/jendso/bvaa167<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metyrapone-pediatric-drug-information/abstract-text/33305159/pubmed" id="33305159" target="_blank">33305159</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18413427">
<a name="18413427"></a>Biller BM, Grossman AB, Stewart PM, et al. Treatment of adrenocorticotropin-dependent Cushing's syndrome: A consensus statement. <i>J Clin Endocrinol Metab</i>. 2008;93(7):2454-2462. doi: 10.1210/jc.2007-2734.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metyrapone-pediatric-drug-information/abstract-text/18413427/pubmed" id="18413427" target="_blank">18413427</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25872515">
<a name="25872515"></a>Bronstein MD, Machado MC, Fragoso MC. Management of endocrine disease: Management of pregnant patients with Cushing's syndrome. <i>Eur J Endocrinol</i>. 2015;173(2):R85-R91. doi: 10.1530/EJE-14-1130.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metyrapone-pediatric-drug-information/abstract-text/25872515/pubmed" id="25872515" target="_blank">25872515</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29523633">
<a name="29523633"></a>Brue T, Amodru V, Castinetti F. Management of endocrine disease: Management of Cushing's syndrome during pregnancy: solved and unsolved questions. <i>Eur J Endocrinol</i>. 2018;178(6):R259-R266. doi:10.1530/EJE-17-1058<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metyrapone-pediatric-drug-information/abstract-text/29523633/pubmed" id="29523633" target="_blank">29523633</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30014438">
<a name="30014438"></a>Ceccato F, Zilio M, Barbot M, et al. Metyrapone treatment in Cushing's syndrome: a real-life study. <i>Endocrine</i>. 2018;62(3):701-711. doi: 10.1007/s12020-018-1675-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metyrapone-pediatric-drug-information/abstract-text/30014438/pubmed" id="30014438" target="_blank">30014438</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26353009">
<a name="26353009"></a>Daniel E, Aylwin S, Mustafa O, et al. Effectiveness of Metyrapone in Treating Cushing's Syndrome: A Retrospective Multicenter Study in 195 Patients. <i>J Clin Endocrinol Metab</i>. 2015a;100(11):4146-4154. doi: 10.1210/jc.2015-2616.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metyrapone-pediatric-drug-information/abstract-text/26353009/pubmed" id="26353009" target="_blank">26353009</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25637072">
<a name="25637072"></a>Daniel E, Newell-Price JD. Therapy of endocrine disease: steroidogenesis enzyme inhibitors in Cushing's syndrome. <i>Eur J Endocrinol</i>. 2015b;172(6):R263-R280. doi: 10.1530/EJE-14-1014.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metyrapone-pediatric-drug-information/abstract-text/25637072/pubmed" id="25637072" target="_blank">25637072</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31041428">
<a name="31041428"></a>Duke ME, Britten FL, Pretorius CJ, et al. Maternal metyrapone use during breastfeeding: Safe for the breastfed infant. <i>J Endocr Soc</i>. 2019;3(5):973-978. doi:10.1210/js.2018-00355<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metyrapone-pediatric-drug-information/abstract-text/31041428/pubmed" id="31041428" target="_blank">31041428</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2217026">
<a name="2217026"></a>Harries-Jones R, Overstall P. Metyrapone-induced alopecia. <i>Postgrad Med J</i>. 1990;66(777):584. doi:10.1136/pgmj.66.777.584<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metyrapone-pediatric-drug-information/abstract-text/2217026/pubmed" id="2217026" target="_blank">2217026</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19759353">
<a name="19759353"></a>Hotham NJ, Ilett KF, Hackett LP, et al, "Transfer of Metyrapone and its Metabolite, Rac-Metyrapol, Into Breast Milk," <i>J Hum Lact</i>, 2009, 25(4):451-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metyrapone-pediatric-drug-information/abstract-text/19759353/pubmed" id="19759353" target="_blank">19759353</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126. doi:10.1056/NEJM200007133430208<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metyrapone-pediatric-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-195666">
<a name="195666"></a>Jeffcoate WJ, Rees LH, Tomlin S, Jones AE, Edwards CR, Besser GM. Metyrapone in long-term management of Cushing's disease. <i>Br Med J</i>. 1977;2(6081):215-217. doi:10.1136/bmj.2.6081.215<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metyrapone-pediatric-drug-information/abstract-text/195666/pubmed" id="195666" target="_blank">195666</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21752886">
<a name="21752886"></a>Kamenický P, Droumaguet C, Salenave S, et al. Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome. <i>J Clin Endocrinol Metab</i>. 2011;96(9):2796-2804. doi: 10.1210/jc.2011-0536.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metyrapone-pediatric-drug-information/abstract-text/21752886/pubmed" id="21752886" target="_blank">21752886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23514671">
<a name="23514671"></a>Kamoun M, Mnif MF, Charfi N, Kacem FH, Naceur BB, Mnif F, Dammak M, et al. Adrenal diseases during pregnancy: pathophysiology, diagnosis and management strategies. <i>Am J Med Sci</i>. 2014;347(1):64-73. doi:10.1097/MAJ.0b013e31828aaeee.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metyrapone-pediatric-drug-information/abstract-text/23514671/pubmed" id="23514671" target="_blank">23514671</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Kliegman RM, Stanton BMD, St. Geme J, Schor NF, eds. <i>Nelson Textbook of Pediatrics</i>. 20th ed. Philadelphia, PA: Saunders Elsevier; 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34425558">
<a name="34425558"></a>Luger A, Broersen LHA, Biermasz NR, et al. ESE clinical practice guideline on functioning and nonfunctioning pituitary adenomas in pregnancy. <i>Eur J Endocrinol</i>. 2021;185(3):G1-G33. doi:10.1530/EJE-21-0462<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metyrapone-pediatric-drug-information/abstract-text/34425558/pubmed" id="34425558" target="_blank">34425558</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21063461">
<a name="21063461"></a>Mancini T, Porcelli T, Giustina A. Treatment of Cushing disease: overview and recent findings. <i>Ther Clin Risk Manag</i>. 2010;6:505-516. doi:10.2147/TCRM.S12952<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metyrapone-pediatric-drug-information/abstract-text/21063461/pubmed" id="21063461" target="_blank">21063461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Metopirone.1">
<a name="Metopirone.1"></a>Metopirone (metyrapone) [prescribing information]. Farmingdale, NJ: Direct Success Inc; February 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26222757">
<a name="26222757"></a>Nieman LK, Biller BM, Findling JW, et al; Endocrine Society. Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2015;100(8):2807-2831. doi: 10.1210/jc.2015-1818.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metyrapone-pediatric-drug-information/abstract-text/26222757/pubmed" id="26222757" target="_blank">26222757</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30352400">
<a name="30352400"></a>Puglisi S, Perotti P, Barbot M, et al. Preoperative treatment with metyrapone in patients with Cushing's syndrome due to adrenal adenoma [published online September 1, 2018]. <i>Endocr Connect</i>. doi: 10.1530/EC-18-0400.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metyrapone-pediatric-drug-information/abstract-text/30352400/pubmed" id="30352400" target="_blank">30352400</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27059746">
<a name="27059746"></a>Uçar A, Baş F, Saka N. Diagnosis and management of pediatric adrenal insufficiency. <i>World J Pediatr</i>. 2016;12(3):261-274.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metyrapone-pediatric-drug-information/abstract-text/27059746/pubmed" id="27059746" target="_blank">27059746</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1657460">
<a name="1657460"></a>Verhelst JA, Trainer PJ, Howlett TA, et al. Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome. <i>Clin Endocrinol (Oxf)</i>. 1991;35(2):169-178.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metyrapone-pediatric-drug-information/abstract-text/1657460/pubmed" id="1657460" target="_blank">1657460</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19675057">
<a name="19675057"></a>Wallace I, Cunningham S, Lindsay J. The diagnosis and investigation of adrenal insufficiency in adults. <i>Ann Clin Biochem</i>. 2009;46(pt 5):351-367. doi: 10.1258/acb.2009.009101.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metyrapone-pediatric-drug-information/abstract-text/19675057/pubmed" id="19675057" target="_blank">19675057</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12607 Version 138.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
